Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

F-Star

Status and phase: Terminated; Phase 2

Conditions: Hepatitis B, Chronic; Hepatitis B; HBV

Treatments: Drug: Tenofovir alafenamide fumarate (TAF); Drug: Inarigivir soproxil

Study type: Interventional

Funder types: Industry

Identifiers

NCT04059198

SBP-9200-HBV-207

Details and patient eligibility

About

An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B treatment-naive subjects with chronic HBV infection.

Enrollment: 5 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. HBV-infected male and female subjects aged 18 to 70 years, inclusive

2. Ultrasound, computed tomography (CT) scan, or magnetic resonance imaging (MRI) within 6 months of enrollment date with no evidence of cirrhosis or hepatocellular carcinoma (HCC)

3. Must be willing and able to comply with all study requirements

4. Chronic HBV as defined by documented HBsAg or HBV DNA positive for 6 months or more

5. Not on any antiviral medications for at least 6 months. If a subject is hepatitis B e antigen (HBeAg)-negative, they will be eligible if they have not received antiviral medications for at least 3 months. Antiviral medications include lamivudine, telbivudine, adefovir, tenofovir, entecavir, IFN therapies of any type, and all other medications with potential antiviral activity.

6. HBV DNA >2000 IU/mL for HBeAg-negative subjects and >20,000 IU/mL for HBeAg-positive subjects at Screening

7. ALT <5× ULN and ≤200 U/L

8. Negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of IP. If the urine pregnancy test is positive, a follow-up serum test is required for confirmation

9. Women of childbearing potential must agree to use a highly effective method of contraception throughout the study and for 3 months after discontinuing study treatment. Men with female partners who are of childbearing potential must agree that they or their partners will use a highly effective method of contraception throughout the study and for 3 months after discontinuing study treatment. Male subjects must not donate sperm throughout the study and for 3 months after discontinuing study treatment.

   • Women of childbearing potential are sexually mature women who have not undergone bilateral tubal ligation, bilateral oophorectomy, or hysterectomy; or who have not been postmenopausal (ie, who have not menstruated at all) for at least 1 year.
   • Highly effective methods of contraception are hormonal contraceptives (oral, injectable, patch, intrauterine devices), male partner sterilization, or total abstinence from heterosexual intercourse, when this is the preferred and usual lifestyle of the subject. Note: The double-barrier method (eg, synthetic condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel), periodic abstinence (such as calendar, symptothermal, post-ovulation), withdrawal (coitus interruptus), lactational amenorrhea method, and spermicide only are not acceptable as highly effective methods of contraception.

10. Must have the ability to understand and sign a written informed consent form (ICF); consent must be obtained prior to initiation of study procedures

Exclusion criteria

1. Any prior liver biopsy evidence of metavir F3 or F4 disease

2. Any history of decompensation of liver disease including history of ascites, encephalopathy, or varices

3. Evidence of advanced fibrosis as defined by Fibroscan at the Screening Visit of ≥8 kPa. If Fibroscan is not available, subjects with both a Fibrotest ≥0.65 and aspartate transaminase (AST):platelet ratio index (APRI) ≥1.0 are excluded (subjects will not be excluded if only 1 of the Fibrotest or APRI results is higher than allowed)

4. Laboratory parameters not within defined thresholds:

   1. White blood cells <4000 cells/μL (<4.0×109/L)
   2. Hemoglobin <11 g/dL (<110 g/L) for females, <13 g/dL (<130 g/L) for males
   3. Platelets <130,000 per μL (<150×109/L)
   4. Albumin <3.5 g/dL (<35 g/L)
   5. International normalized ratio (INR) >1.5
   6. Total bilirubin >1.2 mg/dL (>20.52 μmol/L) or alpha-fetoprotein (AFP) >50 ng/mL (>180.25 nmol/L). Subjects with an elevated indirect bilirubin and known Gilbert's disease can be included if direct bilirubin is within normal limits. Subjects with an AFP >50 ng/mL but <500 ng/mL can be included if CT scan or MRI performed within 3 months shows no evidence of HCC
   7. Creatinine >1.2 mg/dL (>106.08 μmol/L) and creatinine clearance <50 mL/min (<0.83 L/s/m2)

5. Co-infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or hepatitis D virus

6. Evidence or history of HCC

7. Malignancy within 5 years prior to Screening, with the exception of specific cancers that are cured by surgical resection (basal cell skin cancer, etc). Subjects under evaluation for possible malignancy are not eligible

8. Significant cardiovascular, pulmonary, or neurological disease

9. Received solid organ or bone marrow transplant

10. Received within 3 months of Screening or expected to receive prolonged therapy with immunomodulators (eg, corticosteroids) or biologics (eg, monoclonal antibody, IFN)

11. Subjects currently taking medication(s) that are transported through organic anion transporting polypeptide 1 (OATP1) including, but not limited to, atazanavir, rifampin, cyclosporine, eltrombopag, gemfibrozil, lopinavir/ritonavir, and saquinavir

12. Use of another investigational agent within 3 months of Screening

13. Current alcohol or substance abuse judged by the Investigator to potentially interfere with compliance

14. Females who are pregnant or may wish to become pregnant during the study

15. If the Investigator believes the prospective subject will not be able to comply with the requirements of the protocol and complete the study

16. Any medical condition that, in the opinion of the Investigator, could interfere with evaluation of the study objectives or safety of the subjects

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

5 participants in 3 patient groups

Arm 1 - Inarigivir Soproxil Daily

Experimental group

Description:

Inarigivir Soproxil Alone 400 mg Inarigivir daily for 12 weeks followed by 400 mg daily in combination with TAF 25 mg daily for 12 weeks

Treatment:

Drug: Inarigivir soproxil

Drug: Tenofovir alafenamide fumarate (TAF)

Arm 2 - Inarigivir Soproxil 3 Times Weekly

Experimental group

Description:

400 mg Inarigivir 3 times weekly for 12 weeks followed by 400 mg 3 times weekly in combination with TAF 25 mg daily for 12 weeks

Treatment:

Drug: Inarigivir soproxil

Drug: Tenofovir alafenamide fumarate (TAF)

Arm 3 - Inarigivir Soproxil and TAF Daily

Experimental group

Description:

400 mg Inarigivir daily in combination with TAF 25 mg daily for 24 weeks

Treatment:

Drug: Inarigivir soproxil

Drug: Tenofovir alafenamide fumarate (TAF)